My own impression is that the IVM story will turn out the same as the hydroxychloroquine story. For two months (March and April 2020) we required HCQ + azithromycin for all COVID patients (about 150), and, beginning in May 2020, as negative results were pouring in from all over the USA, we made it optional. Use gradually tapered off to zero by August, in part because of the great success we were having with dexamathasone +/- remdesivir (essentially no deaths after May 2020).
1) Why was zinc missing from the HCQ protocol?
HCQ and zinc have a synergistic effect as shown by Zelenko and other successful outcomes from outpatient therapy…prevention of hospitalization being a successful outcome
2) How many people got remdesivir as an outpatient to prevent hospitalization?
Link, please. And who is "we".
Was zinc also pescribed?